alexa A Report on a 7-year Follow up of the Surgical Management with PRGF®- ENDORET® of Oncologic Patients Affected by Intravenous Bisphosphonate Related Osteonecrosis of the Jaw

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

A Report on a 7-year Follow up of the Surgical Management with PRGF®- ENDORET® of Oncologic Patients Affected by Intravenous Bisphosphonate Related Osteonecrosis of the Jaw

Intravenous bisphosphonates (BPs) are the standard therapy in the management of patients with metabolic imbalance involving high bone turnover and increased bone restoration, such as malignant hypocalcaemia, bone metastasis associated with solid tumours and multiple myeloma. In the past years its potentially negative side effects have however caused growing concern; in particular the profound bone remodeling inhibition can cause Bisphosphonate Related Osteo Necrosis of the Jaw (BRONJ), defined as an avascular area of necrotic bone in the maxillofacial area, with or without exposed bone, unable to heal within 8 weeks after its identification by the health care provider in a patient who is or was receiving BP therapy and does not have a previous history of irradiation in the maxillofacial region.

 

For more details: https://www.omicsonline.org/a-report-on-a-7-year-follow-up-of-the-surgical-management-with-prgf-endoret-of-oncologic-patients-affected-by-intravenous-bisphosphonate%20related-osteonecrosis-of-the-jaw-2161-1076.S12-011.php?aid=13260

 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
 
adwords